In research published in the latest edition of the UEG Journal, Scientists in Finland demonstrated that there is variance in the volatile compounds found in the urine of pancreatic cancer patients to that of healthy controls. Research was then undertaken to assess whether FAIMS (Field Asymmetric Ion Mobility Spectrometry) technology could effectively differentiate between pancreatic cancer patients and healthy individuals as a tool for screening. Read more . . .